TY - JOUR
T1 - Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation
T2 - From the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation (CONNECT AF)
AU - FREEDOM AF and CONNECT AF Investigators
AU - Silberberg, Alexandra
AU - Tan, Mary K.
AU - Yan, Andrew T.
AU - Angaran, Paul
AU - Dorian, Paul
AU - Bucci, Claudia
AU - Gregoire, Jean C.
AU - Bell, Alan D.
AU - Gladstone, David J.
AU - Green, Martin S.
AU - Gross, Peter L.
AU - Skanes, Allan
AU - Demchuk, Andrew M.
AU - Kerr, Charles R.
AU - Mitchell, L. Brent
AU - Cox, Jafna L.
AU - Talajic, Mario
AU - Essebag, Vidal
AU - Heilbron, Brett
AU - Ramanathan, Krishnan
AU - Fournier, Carl
AU - Wheeler, Bruce H.
AU - Lin, Peter J.
AU - Berall, Murray
AU - Langer, Anatoly
AU - Goldin, Lianne
AU - Goodman, Shaun G.
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/8/15
Y1 - 2017/8/15
N2 - Using data collected from 2 national atrial fibrillation (AF) primary care physician chart audits (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation [FREEDOM AF] and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation [CONNECT AF]), we evaluated the frequency of, and factors associated with, the use of cardiovascular (CV) evidence-based therapies in Canadian AF outpatients with at least 1 CV risk factor or co-morbidity. Of the 11,264 patients enrolled, 9,495 (84.3%) were eligible for one or more CV evidence-based therapies. The proportions of patients with AF receiving all eligible guideline-recommended therapies were 40.8% of patients with coronary artery disease, 48.9% of patients with diabetes mellitus, 40.2% of patients with heart failure, 96.7% of patients with hypertension, and 55.1% of patients with peripheral arterial disease. Factors that were independently associated with nonreceipt of all indicated evidence-based therapies included sinus rhythm rather than AF at baseline and liver disease. In conclusion, although most Canadian outpatients with AF have CV risk factors or co-morbidities, a substantial portion of these patients did not receive all guideline-recommended therapies. These findings suggest that there is an opportunity to improve the quality of care for patients with AF in Canada.
AB - Using data collected from 2 national atrial fibrillation (AF) primary care physician chart audits (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation [FREEDOM AF] and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation [CONNECT AF]), we evaluated the frequency of, and factors associated with, the use of cardiovascular (CV) evidence-based therapies in Canadian AF outpatients with at least 1 CV risk factor or co-morbidity. Of the 11,264 patients enrolled, 9,495 (84.3%) were eligible for one or more CV evidence-based therapies. The proportions of patients with AF receiving all eligible guideline-recommended therapies were 40.8% of patients with coronary artery disease, 48.9% of patients with diabetes mellitus, 40.2% of patients with heart failure, 96.7% of patients with hypertension, and 55.1% of patients with peripheral arterial disease. Factors that were independently associated with nonreceipt of all indicated evidence-based therapies included sinus rhythm rather than AF at baseline and liver disease. In conclusion, although most Canadian outpatients with AF have CV risk factors or co-morbidities, a substantial portion of these patients did not receive all guideline-recommended therapies. These findings suggest that there is an opportunity to improve the quality of care for patients with AF in Canada.
UR - http://www.scopus.com/inward/record.url?scp=85021811515&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021811515&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2017.05.027
DO - 10.1016/j.amjcard.2017.05.027
M3 - Article
C2 - 28666577
AN - SCOPUS:85021811515
SN - 0002-9149
VL - 120
SP - 582
EP - 587
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 4
ER -